PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21957896-0 2011 The effect of quinapril treatment on insulin resistance, leptin and high sensitive C-reactive protein in hypertensive patients. Quinapril 14-23 insulin Homo sapiens 37-44 11204290-0 2001 Quinapril treatment enhances vascular sensitivity to insulin. Quinapril 0-9 insulin Homo sapiens 53-60 11204290-4 2001 DESIGN AND METHODS: The effects of 3 months of therapy with quinapril on vascular sensitivity to insulin was assessed in 11 hypertensive subjects using a randomized, placebo-controlled, double-blind design. Quinapril 60-69 insulin Homo sapiens 97-104 11204290-7 2001 RESULTS: Quinapril therapy significantly improved vascular sensitivity to insulin, as assessed by a decrease in the ED50 for insulin (ED50 insulin: placebo = 501 +/- 189 [muU/ min; quinapril = 276 +/- 100 muU/min P < 0.05). Quinapril 9-18 insulin Homo sapiens 74-81 11204290-7 2001 RESULTS: Quinapril therapy significantly improved vascular sensitivity to insulin, as assessed by a decrease in the ED50 for insulin (ED50 insulin: placebo = 501 +/- 189 [muU/ min; quinapril = 276 +/- 100 muU/min P < 0.05). Quinapril 9-18 insulin Homo sapiens 125-132 11204290-7 2001 RESULTS: Quinapril therapy significantly improved vascular sensitivity to insulin, as assessed by a decrease in the ED50 for insulin (ED50 insulin: placebo = 501 +/- 189 [muU/ min; quinapril = 276 +/- 100 muU/min P < 0.05). Quinapril 9-18 insulin Homo sapiens 125-132 11204290-7 2001 RESULTS: Quinapril therapy significantly improved vascular sensitivity to insulin, as assessed by a decrease in the ED50 for insulin (ED50 insulin: placebo = 501 +/- 189 [muU/ min; quinapril = 276 +/- 100 muU/min P < 0.05). Quinapril 181-190 insulin Homo sapiens 74-81 11204290-9 2001 CONCLUSIONS: The current study suggests the hypothesis that the ACE-inhibitor quinapril has beneficial effects on vascular function in general, and on insulin-mediated vascular responses, in particular. Quinapril 78-87 insulin Homo sapiens 151-158 8466592-3 1993 The insulin effect was only partially inhibited by the converting enzyme inhibitors enalapril, quinapril, and quinaprilat, whereas it was markedly or totally blunted by the angiotensin II antagonists DuP753 and PD123177. Quinapril 95-104 insulin Homo sapiens 4-11 16352688-0 2006 Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. Quinapril 0-9 insulin Homo sapiens 30-37 16352688-2 2006 We hypothesized that 2 months of quinapril treatment would improve insulin-stimulated endothelial function and glucose uptake in type 2 diabetic subjects and simultaneously increase the expression of genes that are pertinent for endothelial function and metabolism. Quinapril 33-42 insulin Homo sapiens 67-74 16352688-8 2006 RESULTS: Quinapril treatment increased insulin-stimulated endothelial function in the type 2 diabetic subjects (P = 0.005), whereas forearm glucose uptake was unchanged. Quinapril 9-18 insulin Homo sapiens 39-46 16352688-12 2006 CONCLUSIONS: Quinapril treatment increases insulin-stimulated endothelial function in patients with type 2 diabetes. Quinapril 13-22 insulin Homo sapiens 43-50 10095796-10 1998 RESULTS: In the quinapril group, the fasting serum glucose, oral glucose tolerance and the C-peptide and insulin responses, determined as the incremental area under the curves (AUC), showed no change, but the mean HbA1c level increased from 6.2 +/- 1.1% to 6.5 +/- 1.3% (P < 0.05). Quinapril 16-25 insulin Homo sapiens 105-112 10095796-15 1998 Although treatment with quinapril or metoprolol over 6 months was concomitant with a rise in the HbA1c, increased fasting blood glucose, decreased oral glucose tolerance and decreased C-peptide and insulin responses to a glucose challenge were observed only in patients treated with metoprolol. Quinapril 24-33 insulin Homo sapiens 198-205 7576397-8 1995 The results confirm that quinapril is an effective antihypertensive agent that additionally reduces microalbuminuria in both hypertensive diabetics and in patients with essential hypertension, without altering insulin sensitivity and lipid profiles. Quinapril 25-34 insulin Homo sapiens 210-217 21957896-5 2011 Quinapril may be used as a therapy for improving blood pressure as well as the insulin resistant, hyperleptinemic, and low-grade inflammatory state in hypertension. Quinapril 0-9 insulin Homo sapiens 79-86